Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Tax Provisions (2020 - 2025)

Historic Tax Provisions for UroGen Pharma (URGN) over the last 6 years, with Q3 2025 value amounting to -$1.1 million.

  • UroGen Pharma's Tax Provisions fell 125824.18% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 2563.78%. This contributed to the annual value of $2.8 million for FY2024, which is 2775.51% down from last year.
  • UroGen Pharma's Tax Provisions amounted to -$1.1 million in Q3 2025, which was down 125824.18% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Tax Provisions peaked at $3.9 million during Q4 2023, and registered a low of -$1.1 million during Q3 2025.
  • Moreover, its 5-year median value for Tax Provisions was $312000.0 (2021), whereas its average is $606411.8.
  • Examining YoY changes over the last 5 years, UroGen Pharma's Tax Provisions showed a top increase of 257105.26% in 2025 and a maximum decrease of 125824.18% in 2025.
  • UroGen Pharma's Tax Provisions (Quarter) stood at $1.1 million in 2021, then plummeted by 39.4% to $689000.0 in 2022, then surged by 459.36% to $3.9 million in 2023, then plummeted by 31.27% to $2.6 million in 2024, then plummeted by 139.79% to -$1.1 million in 2025.
  • Its Tax Provisions stands at -$1.1 million for Q3 2025, versus $1.0 million for Q2 2025 and $392000.0 for Q1 2025.